Steve Dingman

Steve Dingman is currently the Vice President of Pharmacovigilance and Head of Safety at Merus N.V., a role they have held since 2025. Previously, they served as the Vice President of Drug Safety and Pharmacovigilance at Alkermes from 2021 to 2022, and as Vice President of Pharmacovigilance at ImmunoGen, Inc. from 2022 to 2025. Their earlier experience includes positions such as Senior Medical Director of Global Pharmacovigilance at AbbVie and Global Drug Safety Physician at UCB Pharma. Steve is pursuing a BA in Finance at the University of Iowa, a BA in Chemistry at North Carolina State University, and an MD at the University of North Carolina at Chapel Hill.